Showing 4631-4640 of 9717 results for "".
- AI in Action: New Machine Learning Technique May Enhance Computer-aided Diagnosis of Melanomahttps://practicaldermatology.com/news/ai-in-action-new-machine-learning-technique-may-enhance-computer-aided-diagnosis-of-melanoma/2457963/Researchers at Florida Atlantic University’s College of Engineering and Computer Science have developed a technique using machine learning – a sub-field of artificial intelligence (AI) – that will enha
- FDA Approves Janssen's Golimumab for PsA, AShttps://practicaldermatology.com/news/fda-approved-jansens-golimumab-for-psa-as/2457998/The FDA approved Janssen’s SIMPONI ARIA (golimumab) for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Simponi is the only fully-human anti-tumor necrosis factor (TNF
- Five ASDS Members Receive President's Awards at Annual Meetinghttps://practicaldermatology.com/news/five-asds-members-receive-presidents-awards-at-annual-meeting/2458024/Five members of the American Society for Dermatologic Surgery (ASDS) received President’s Awards for their contributions to the Society and dermatologic specialty at the 2017 ASDS Annual Meeting in Chicago. The 2017 recipients were Murad Alam, MD,
- Two Galderma Rosacea Therapies Work Well Togetherhttps://practicaldermatology.com/news/two-galderma-rosacea-therapies-work-well-together/2458061/Combined use of Galderma’s SOOLANTRA (ivermectin1% Cream) and Mirvaso (Brimonidine 0.33% Gel) pack a one-two punch against the erythema and inflammatory lesions of rosacea, the MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCe
- FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseaseshttps://practicaldermatology.com/news/fda-greenlights-humira-biosim-cyltezo-for-multiple-inflammatory-diseases/2458073/The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including:
- Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in EBhttps://practicaldermatology.com/news/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-cell-therapy-in-eb/2458075/The U.S. Food and Drug Administration granted Breakthrough Therapy Designation status to the Abeona Therapeutics Inc.’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa. EB-101 is an autologous,&
- FDA Clears Clarify Medical Core Technology for At-home UVB Phototherapyhttps://practicaldermatology.com/news/fda-clears-clarify-medical-core-technology-for-at-home-uvb-phototherapy/2458165/The US Food and Drug Administration has cleared the Clarify Medical Phototherapy System for marketing, and the new smart, at-home UVB phototherapy system will be available to patients with chronic skin diseases in November. Clarify’s proprie
- Allergan and Paratek Pharmaceuticals' Acne Drug Performs Well in Phase 3 Trialshttps://practicaldermatology.com/news/allergan-and-paratek-pharmaceuticals-acne-drug-performs-well-in-phase-3-trials/2458234/Allergan and Paratek Pharmaceuticals, Inc.’s investigational acne drug performed well in two Phase 3 studies, the companies report. Sarecycline, a once-daily, oral, narrow spectrum tetracycline-derived anti
- Crescita Therapeutics Announces Management and Board Changeshttps://practicaldermatology.com/news/crescita-therapeutics-announces-management-and-board-changes/2458293/Crescita Therapeutics Inc., a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, introduced Ms. Muneerah Kanji, MBA, CPA, CA, Crescita's Corporate Controll
- Valeant Appoints William D. Humphries As EVP, Dermatologyhttps://practicaldermatology.com/news/valeant-appoints-william-d-humphries-as-evp-dermatology/2458348/Valeant Pharmaceuticals International, Inc. appointed William D. Humphries as Executive Vice President, Dermatology, effective January 2, 2017. Mr. Humphries will join Valeant's Executive Committee, reporting directly to